Tirzepatide vs Semaglutide: What the Head-to-Head Trial Actually Found

The mechanical difference

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut releases after eating, which slows gastric emptying, increases satiety and reduces appetite signalling in the brain. It is sold as Wegovy for weight management and Ozempic for type 2 diabetes.

Tirzepatide is a dual agonist. It activates the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP appears to add effects on fat metabolism and may improve tolerability at a given level of appetite suppression. It is sold as Zepbound for weight management and Mounjaro for type 2 diabetes.

That second receptor is the whole argument for tirzepatide, and the trial data supports it.

What the trials showed

• STEP-1 tested semaglutide 2.4 mg in adults with obesity. Mean weight reduction was about 14.9% over 68 weeks.
• SURMOUNT-1 tested tirzepatide in adults with obesity. Mean weight reduction at the 15 mg dose was about 20.9% over 72 weeks.

Comparing across separate trials is unreliable, because the populations and protocols differ. The useful evidence arrived with SURMOUNT-5, a direct head-to-head trial. Over 72 weeks, tirzepatide produced roughly 20.2% mean weight reduction against roughly 13.7% for semaglutide. Tirzepatide won, and the margin was not marginal.

What that means in practice

For a 220 lb starting weight, those averages work out to roughly 44 lb on tirzepatide against roughly 30 lb on semaglutide. Averages hide enormous individual variation: some people respond strongly to semaglutide and poorly to tirzepatide, and dose, adherence, diet and activity all move the number.

Greater efficacy is not automatically the right goal either. Rapid weight loss carries a higher proportion of lean mass loss, and appetite suppression strong enough to make eating adequate protein difficult is a real problem, not a sign of success.

Side effects

Both drugs share the same profile: nausea, diarrhoea, vomiting, constipation and abdominal pain, mostly during dose escalation and mostly improving with time. Both carry a boxed warning about thyroid C-cell tumours observed in rodents, and both are contraindicated if you or a close relative have had medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

In SURMOUNT-5 the discontinuation rates for side effects were broadly comparable, which undercuts the common claim that tirzepatide is decisively gentler. Some people tolerate one far better than the other, and there is no reliable way to predict which in advance.

Read more in our guide to GLP-1 side effects and who should not take them.

Cost

Tirzepatide costs more, consistently. Across the compounded providers we track, semaglutide starts around $99–$179 a month and tirzepatide around $139–$209. Brand-name routes run considerably higher.

Full breakdown in how much tirzepatide really costs, or use the cost calculator.

Which should you ask about?

On the evidence, tirzepatide is the more effective drug for weight loss. Semaglutide is cheaper, has a longer real-world track record, and has cardiovascular outcome data behind it.

This is a decision for you and a prescriber who knows your history, not a decision to make from a comparison table. What a table can tell you is what each route costs, which is what our provider comparison is for.

Questions people ask about this

• Which GLP-1 is best for weight loss?
• Which GLP-1 is best for cardiovascular benefit?
• How fast does GLP-1 weight loss happen?
• What does GLP-1 do in the body?
• Is there an oral GLP-1?

Related guides

• Compounded vs Brand-Name GLP-1: Cost, Legality and What Actually Differs
• How Much Does Tirzepatide Cost in 2026? Every Route Priced
• GLP-1 Side Effects and Who Should Not Take Them
• Microdosing GLP-1s: What It Is and Who It Actually Helps
• How to Get Tirzepatide or Semaglutide Without Insurance
• The 8 best GLP-1 providers, compared

↑ Back to top